The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

A Celtic supporting father-of-two who was once nicknamed “Fat Pal” by his friends has dropped five stone in five months after ...

GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy ...

In the US, tirzepatide is sold as Mounjaro for diabetes and under the Zepbound brand for overweight and obesity and is currently available in the original singe-dose pen-injector format.

Tirzepatide has dual-action mechanism- it targets both GLP ... In the United States, it is marketed in pen form, whereas in India, it is sold in Vial form making 80% cheaper in India than in the U.S.

"Payments by Pfizer hold the potential to induce specific actions of the prescribing pen." Both Lilly and Pfizer claim their programmes tap into the increased willingness of patients to use ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

The study, led by Dr. Luca Busetto from the University of Padova in Italy and colleagues from Eli Lilly and Company that manufacture tirzepatide, is a continuation of the SURMOUNT-1 phase 3 trial ...

Consistent with known effects of GLP-1/GIP therapy, over 50% of lost weight was regained within two weeks of stopping treatment in both the tirzepatide and co-administration arms of the study.

Image credit: NurPhoto/Getty Images. According to a new study, a once-weekly dose of tirzepatide can lead to significant, sustained weight loss for up to 3 years in adults with overweight or ...

Jamie Mafdali of South Florida was hit with a cancer double-whammy three years ago. Shortly after her mother began treatment ...